| Q40408515 | Drug-induced hypersensitivity syndrome associated with reactivation of human herpesvirus 6 presenting with severe hepatic injury |
| Q39814847 | Effect of Thiol-reducing Agents and Antioxidants on Sulfasalazine-induced Hepatic Injury in Normotermic Recirculating Isolated Perfused Rat Liver |
| Q72923486 | Fulminant hepatic failure |
| Q38814158 | Hepatic manifestations of inflammatory bowel diseases |
| Q26773684 | Hepatic manifestations of non-steroidal inflammatory bowel disease therapy |
| Q55114620 | Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. |
| Q24804632 | Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis |
| Q35040109 | Liver abnormalities in rheumatic diseases |
| Q37827164 | Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. |
| Q34585315 | Review article: monitoring for drug side-effects in inflammatory bowel disease |
| Q33503944 | Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin |
| Q42183819 | Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine |
| Q40432257 | Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis |
| Q40594422 | The 3-week sulphasalazine syndrome strikes again |